The shares of Selecta Biosciences Inc. (NASDAQ:SELB) has been pegged with a rating of Overweight by Cantor Fitzgerald in its latest research note that was published on January 29, 2020. The Healthcare company has also assigned a $10 price target. Cantor Fitzgerald wasn’t the only research firm that published a report of Selecta Biosciences Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Buy rating from Janney Markets when it published its report on June 27, 2018. That day the Janney set price target on the stock to $33. The stock was given Buy rating by UBS in its report released on March 30, 2017, the day when the price target on the stock was placed at 26.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 7 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $8.17. The price of the stock the last time has raised by 67.19% from its 52-Week high price while it is -55.69% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 40.45.
The shares of the company added by 9.74% during the trading session on Wednesday, reaching a low of $1.85 while ending the day at $2.14. During the trading session, a total of 653438.0 shares were traded which represents a 11.31% incline from the average session volume which is 736800.0 shares. SELB had ended its last session trading at $1.95. Selecta Biosciences Inc. debt-to-equity ratio currently stands at 2.25, while its quick ratio hovers at 2.80 SELB 52-week low price stands at $1.28 while its 52-week high price is $4.83.
The company in its last quarterly report recorded -$0.28 earnings per share which is below the predicted by most analysts. The Selecta Biosciences Inc. generated 90.17 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.26 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -10.71%. Selecta Biosciences Inc. has the potential to record -1.12 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Ladenburg Thalmann published a research note on January 06, 2020 where it informed investors and clients that Sunnova Energy International Inc. (NYSE:NOVA) is now rated as Buy. Their price target on the stock stands at $15. ROTH Capital also rated NOVA as Initiated on August 20, 2019, with its price target of $15 suggesting that NOVA could surge by 43.19% from its current share price. Even though the stock has been trading at $10.90/share, analysts expect it to surge by 9.45% to reach $21.00/share. It started the day trading at $12.49 and traded between $10.21 and $11.93 throughout the trading session.
The stock has a high of $20.87 for the year while the low is $6.12. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 646553.88 shorted shares, the short percentage went higher by 7.28%, as 693,623 SELB shares were shorted. At the moment, only 1.64% of Sunnova Energy International Inc. shares were sold short. The company’s average trading volume currently stands at 563.75K shares, which means that the short-interest ratio is just 1.15 days. Over the past seven days, the company moved, with its shift of 70.43%. Looking further, the stock has raised 4.47% over the past 90 days while it gained 2.93% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Handelsbanken Fonder AB bought more NOVA shares, increasing its portfolio by 16.20% during the last quarter. This move now sees The Handelsbanken Fonder AB purchasing 432,393 shares in the last quarter, thus it now holds 3,100,864 shares of NOVA, with a total valuation of $53,644,947.
Similarly, Clal Pension & Provident Funds Lt… increased its Sunnova Energy International Inc. shares by 17.65% during the recently filed quarter. After buying 2,000,000 shares in the last quarter, the firm now controls 300,000 shares of Sunnova Energy International Inc. which are valued at $34,600,000. In the same vein, Fidelity Management & Research Co… increased its Sunnova Energy International Inc. shares by during the most recent reported quarter. The firm bought 749,100 shares during the quarter which increased its stakes to 1,861,900 shares and is now valued at $32,210,870. Following these latest developments, around 8.50% of Sunnova Energy International Inc. stocks are owned by institutional investors and hedge funds.